Psychiatric illnesses may be qualified to the cellular impairments of the function for survival
or death in neurons, which may consequently appear as abnormalities in the neuroplasticity …

Several pharmacological agents acting on monoamine neurotransmission are used for the
management of mental illnesses. Regulation of PI3K/AKT and GSK3 pathways may …

Schizophrenia is a prevalent complex trait disorder manifested by severe neurocognitive
dysfunctions and lifelong disability. During the past few years several studies have provided …

Abstract Disruption of Akt and Erk-mediated signal transduction significantly contributes in
the pathogenesis of various neurodegenerative diseases (NDs), such as Parkinson's …

Psychotropic drugs acting on monoamine neurotransmission are major pharmacological
treatments for neuropsychiatric conditions such as schizophrenia, depression, bipolar …

Increased GSK-3 activity is believed to contribute to the etiology of chronic disorders like
Alzheimer's disease (AD), schizophrenia, diabetes, and some types of cancer, thus …

Overexpression of GSK3β in transgenic mice induces learning deficits and some features
associated with Alzheimer's disease (AD), including dentate gyrus (DG) atrophy. Here, we …

Neuroanatomical studies of brains from schizophrenic patients report evidence for neuronal
dystrophy, while in genetic studies in schizophrenia there is evidence for mutations in …

Parkinson's disease is a common progressive and multifactorial neurodegenerative disease,
characterized by the loss of midbrain dopaminergic neurons. Numerous pathological …

Glycogen synthase kinase-3 (GSK-3) is a widely expressed and highly conserved
serine/threonine protein kinase encoded in mammals by two genes that generate two …